NCT00523913View on ClinicalTrials.gov

A Study Of BRL49653C For The Treatment Of Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL

Enrollment

70

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

April 30, 2007

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

rosiglitazone

Trial Locations (1)

Unknown

GSK Investigational Site

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00523913 - A Study Of BRL49653C For The Treatment Of Type 2 Diabetes | Biotech Hunter | Biotech Hunter